Central nervous system (CNS) diseases include various infections (meningitis and encephalitis), structural impairment (brain or spinal injury), vascular issues (stroke and other hemorrhages), functional issues (epilepsy and migraines), and neurodegenerative conditions (Alzheimer’s and Parkinson’s disease). Due to constant increase in the size and age of the world population, the prevalence of these diseases will also increase, and thus become a priority area of research studies.
The development of therapeutic strategies for CNS disorders is challenging, as the cells involved have a considerable diversity, complexity of neural circuits and associated functions, poor tissue regeneration, and incomplete understanding of the underlying pathological processes.
The global central nervous system disorders therapeutics market is estimated to be valued at US$ 97,028.1 million in 2021 and is expected to exhibit a CAGR of 7.4% during the forecast period (2021-2028).
Figure 1.Global Central Nervous System Disorders Therapeutics Market Share (%) in Terms of Value, by Drug Class, 2021
Increasing prevalence of CNS disorders is expected to propel the growth of the global central nervous system disorders therapeutics market during the forecast period.
The increasing prevalence of CNS disorders is expected to propel the growth of the global central nervous system disorders therapeutics market during the forecast period. For instance, according to MedScape, a leading online global destination offering the latest medical news and expert perspectives, in 2019, the global prevalence of Parkinson’s disease was estimated to be 18-328 cases per 100,000 population per year. Moreover, according to the World Health Organization (WHO) report 2020, about 50 million people across the world were suffering from dementia in 2019. The same source reveals that approximately 10 million new cases of dementia are reported every year, out of which most of the cases are associated with Alzheimer’s disease.
|Base Year:||2020||Market Size in 2021:||US$ 97,028.1 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||7.4%||2028 Value Projection:||US$ 159,583.2 Mn|
Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
|Restraints & Challenges:||
Figure 2.Global Central Nervous System Disorders Therapeutics Market Share (%), by Distribution Channel, 2021
Rising number of product launches and approvals is expected to drive the growth of the global central nervous system disorders therapeutics market over the forecast period.
The rising number of product launches and approvals is expected to drive the growth of the global central nervous system disorders therapeutics market over the forecast period. For instance, in April 2020, Neurocrine Biosciences, Inc., a U.S.-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for its drug Ongentys, which is used to treat Parkinson’s disease.
Global Central Nervous System Disorders Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected the entire pharmaceutical industry supply chain, mainly due to the strict lockdown in various regions. However, demand for central nervous system disorders therapeutics is expected to increase during pandemic due to the association of neurological diseases (such as depression, anxiety and others) with COVID-19 infection. For instance, according to an article published in June 2021, in the journal Alzheimer's Research & Therapy, a study from the Cleveland Clinic, showed a close association between coronavirus genes and Alzheimer's disease. The study showed that SARSCoV2 infection resulted in multiple signaling pathways related to neuroinflammation and microvascular injury in the brain, which can also lead to cognitive decline.
Thus, impact of the Coronavirus (COVID-19) pandemic is expected to fuel growth of the global central nervous system disorders therapeutics market during the forecast period, owing to rising neurological disorders, as a result of COVID-19 infection during the pandemic.
According to the United Nations-Policy Brief: COVID-19 and the Need for Action on Mental Health published in May 2020, specific populations groups have been affected by COVID-19 in different ways. For instance, in Canada, 47% of health-care workers reported a need for psychological support. Moreover, in the People’s Republic of China, healthcare workers reported high rates of depression (50%), anxiety (45%), and insomnia (34%).
Global Central Nervous System Disorders Therapeutics Market: Restraint
The major factors that hinder growth of the global central nervous system disorders therapeutics market include adverse effects associated with CNS disorder drugs, time consuming drug development, and approval process.
Major players operating in the global central nervous system disorders therapeutics market include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.
A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.
The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.